Search results for "oligonucleotide" in Articles / App Notes

Article Transformative Medicines Challenge FDA and Manufacturers
Biopharma researchers also are achieving success in developing oligonucleotide therapies, including antisense drugs and short interfering RNA treatments (siRNAs) that can modulate immune pathways. Saf…

Article Are you ready to optimize your oligo synthesis?
Read it now to explore five key areas in your oligonucleotide chemistry where improvements will have a huge influence on the quality outcome of your synthesis. Learn more

Article How can you harness the potential of nucleic acid therapeutics?
At Cytiva, the new team is here to support you. We can help you throughout the development of your manufacturing workflow for oligonucleotides and the purification of mRNA drug subs…

Article Top Process Development Trends for 2021 and a Look into 2022
…iruses for delivery; oligo-based therapeutics such as anti-sense DNA, siRNA, mRNA, splice-switching oligonucleotides, and immune-stimulatory oligonucleotides; extracellular vesicles and exosomes such…

Article A Look at the Affinity Chromatography Landscape
Other libraries consist of polypetides produced by means of phage display and/or ribosome display and aptamers, short single-stranded RNA or DNA oligonucleotides that spontaneously fold into structure…

Article Automated Concentration and Diafiltration of Multiple siRNA Samples
PROCESS DESCRIPTION The production of RNA oligonucleotides in the process workflow begins with chemical synthesis using the ÄKTAoligopilot platform to create single-stranded RNA (ssRNA)…

Article Ready for a strong start in oligo manufacturing?
Are you interested in manufacturing your own oligonucleotide therapeutics but don’t know how to start? Or are you already manufacturing your own oligos but are running into challenges? If so, …

Article Top Process Development Trends for 2022 and a Look into 2023
Providing real-world advice from experts was met in the question-and-answer session on oligonucleotide synthesis scale up by Greg Farlow from Cytiva. While this certificate-level interactive course on…

Article Future Downstream Process Development Solutions for Advanced Therapies
Related Content Q&As with Industry Leaders mRNA manufacturing strategies Manufacturing of viral vectors  Purification of plasmids  Oligonucleotide therapeutics 

Article Gene Therapies Push Viral Vector Production
“Apart from plasmids there are liposomes, lipoplexes, polyplexes, and oligonucleotides [that can be used] as non-viral modes of gene delivery.” Vicaire also notes that using non-viral vehicles …

Show All Results

Previous PageNext Page